Scientific Director Cum Owner Dr Kulvinder Kaur Centre for Human Reproduction, Jalandhar, Punjab, India
Reproductive endocrinologists as well as infertility specialists (REIs) have substantially refined the therapy of infertility by idealization of in vitro fertilization (IVF), i) from controlled ovarian stimulation ii) to advancements in the laboratory in fertilization, iii) culture, iv) preimplantation testing, in addition to v) cryopreservation. IVF resulted in conversion of bothersome infertility patients from a situation where we possessed the capability of practically negligible performance regarding therapy in contrast to presently possessing the capacity of managing it efficaciously. In reference to reproduction metabolic health possesses core part, however therapy did not propagate owing to i) lifestyle alteration, ii) earlier anti-obesity medications, along with iii) weight-loss surgery work unpredictably or gradually against the time pressures our patients face. Glucagon-like peptide-1 (GLP-1) receptor agonists are the in initial first medications to alter that, as well as apparently, they serve for metabolic health which IVF portrayed for infertility. The query posed for REIs is the magnitude we proceed to use them to treat the metabolic health.
Wolfe., et al. [1] conducted a cross-sectional survey recently which pointed that plethora of clinicians had already started addressing that query. Surveying fertility specialists regarding their utilization of weight- reduction anti-obesity agents fundamentally GLP-1 as well as double GLP-1/GIP receptor agonists, the researchers observed that approximately i) 50% believed prescribing to be amongst the scope of fertility care, ii) roughly 50% were already using, in addition to iii) practically 50% anticipated to start/persist or continue across the subsequent one to two years. Respondents’ maximum frequently prescribed to refine metabolic health prior to conception, in addition to they isolated the absence of clear criterion along with their own unfamiliarity in the form of the major expositions they were not sure. The sample is minute one along with self-selected, obtained from 35 researchers who adequately decided to go to a seminar on the subject, as well as it is not paradigmatic of a national sample. The survey is most noticeable for the lacunae it documents: REIs are already prescribing such medications without parameters to guide them.
The interest was well initiated, owing to such medicines generate about 15% weight reduction, with advantages which are inclusive of cardiovascular as well as metabolic health [2]. The botheration is that such utilization has advanced swiftly over the corroboration needed to manage them in the scenario of infertility. A 2026 nationwide cohort study illustrated that the prevalence of GLP-1 RA prescribing escalated from 0.2 to 6.4 per 1, 000 deliveries predelivery, from 2019 to 2024 [3], making equivalent to roughly 20, 000 pregnancies in 2024 alone, a tendency that has maximum frequently persisted. Best practices for management in the preconception window along with early pregnancy are considerably lacking from the obesity-medicine literature: is the time of omission of such medicine germane to conception, the manner of tackling the resurgence of appetite in addition to weight when the drug is discontinued for fertility therapy along with the manner of dampening rebound weight escalation in pregnancy. The early data yielded expositions for being cautious. A 2025 cohort study, comprised basically of women with obesity, observed that omission of prior to - or in early pregnancy was correlated with higher gestational weight gain as well as with greater rates of i) preterm delivery, ii) gestational diabetes, in addition to iii) hypertensive disorders of pregnancy [4]. The observations are uniform with what insight we possess beforehand regarding weight rebound, along with it toughening any anticipation of that weight reduction on a GLP-1 receptor agonist would be sustained subsequent to discontinuation of the drug for pregnancy toughens.
Prescription of a GLP-1 receptor agonist simply with the idea of weight reduction followed by subsequent omission at conception, without any alteration in the patient’s therapy, might result in attainment of short-term weight reduction whereas not diminishing her metabolic in addition to pregnancy complications risk. Nonetheless prescription in a structured program with nutritional along with behavioral embracing might aid in good preparation in reference to sustenance of weight reduction subsequent to omission with a concentrated option on how to time omission of at the time of conception right from the beginning outset. Trials need to be conducted in reference to how such a program is carried out for patients switching from a GLP-1 receptor agonist toward conception, as well as fashioning one is among the greater use that we REIs are capable of making contributions towards our specialty. An additional query gets invoked by biology. GLP-1 receptors are expressed in the pituitary, ovary, as well as endometrium [5], in addition to preclinical work points reproductive actions which may be partially autonomous of weight reduction. If such agents refine fertility directly, in addition to the advantages following obesity therapy, continue to be uncharted, however in the form of REIs our specialty is well placed to provides any answer.
Therefore practically, we are the ones prescribing GLP-1 receptor agonists need to utilize a program which yields other ingredients of obesity care, instead of a single addition to an IVF program. The ones not possessing the capability of building this need not stop prescription, as well as increase patients to seek multiple specialists, rather need to align with obesity-medicine dr for patients sake. Obesity is a chronic disease, along with our patients therapy is refined if we treat it to give better results with obese cases.
These medications are actually good advancements, in addition to they deserve the structure in addition to which enable effectiveness whereas diminishing any inadvertent causation of inimicality. Nonetheless this survey does not impart any guidance for GLP-1 receptor agonist regarding GLP-1 receptor agonist assuming a part in thorough improvement for our patients’ therapy of conception however to further their metabolic health as well as outcome of the pregnancy in form of epigenetic changes following in offspring is needed.
Kulvinder Kochar Kaur. “How to Idealize Utilization of GLP-1 RA in Infertility Practices from Timing of Omission Prior to Con- ception to Add in Bettering Offspring Avoidance of Complications in Offsprings Regarding Epigenetic and other complications in Obese Infertile Cases ”. EC Gynaecology 15.9 (2026): 01-02.
© 2026 Kulvinder Kochar Kaur. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Open Access by ECronicon is
licensed under a Creative Commons Attribution
4.0 International License
Based on a work at www.ecronicon.net
